Oxana Beskrovnaya - Nov 15, 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Scientific Officer
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Stock symbol: DYN
Transactions as of: Nov 15, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/16/2023, 04:23 PM
Previous filing: Sep 20, 2023
Next filing: Dec 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+93.7K	+111.13%	$0.00	178K	Nov 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (right to buy)	Award	$0	+36.5K		$0.00	36.5K	Nov 15, 2023	Common Stock	36.5K	$10.88	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 93,718 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024.
F2	Includes 151,588 unvested RSUs.
F3	This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027.